Nurix Therapeutics Inc
NRIX
NASDAQ
Biotechnology
$27.05
USD
-0.14 (-0.51%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.79B
Volume 738.2K
Revenue
$36.77M
TTM
-58.4%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-341.35M
TTM
-64.6%
YoY
Operating Cash Flow
$-293.70M
TTM
-36.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 44.1 | 7.9 | 13.6 | 6.3 | 9.0 |
YoY Growth | +264.3% | -37.3% | +2.2% | -66.1% | -79.5% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 44.1 | 7.9 | 13.6 | 6.3 | 9.0 |
Selling, General & Administrative | 14.3 | 13.2 | 13.6 | 14.6 | 15.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 92.4 | 99.3 | 96.7 | 98.7 | 103.2 |
Operating Income | -48.3 | -91.4 | -83.1 | -92.5 | -94.2 |
EBITDA | -46.1 | -89.4 | -81.0 | -90.3 | -91.9 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 5.6 | 5.0 | 4.9 | 5.3 | 4.4 |
Income Before Income Taxes | -42.7 | -86.4 | -78.2 | -87.2 | -89.8 |
Income Taxes | 0.8 | 0.0 | 0.0 | 0.0 | -0.3 |
Net Income | -43.5 | -86.4 | -78.2 | -87.2 | -89.5 |
Consolidated Net Income / Loss | -43.5 | -86.4 | -78.2 | -87.2 | -89.5 |
Net Income Attributable to Common Shareholders | -43.5 | -86.4 | -78.2 | -87.2 | -89.5 |
Basic EPS | -$0.52 | -$1.03 | -$0.82 | -$0.79 | -$0.81 |
Diluted EPS | -$0.52 | -$1.03 | -$0.82 | -$0.79 | -$0.81 |
Basic Shares Outstanding | 83.9M | 84.2M | 95.1M | 110.1M | 111.1M |
Diluted Shares Outstanding | 83.9M | 84.2M | 95.1M | 110.1M | 111.1M |